Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: Posthumous sperm donation is technically feasible and morally acceptable, the specialists said in a review published in the Journal of Medical Ethics on Tuesday. They argue it should be seen like organ and other tissue donations as a way of relieving the suffering of others. While infertility is not life-threatening, said Nathan Hodson of Britain's Leicester University and Joshua Parker of Britain's Wythenshawe Hospital in Manchester, it causes great suffering and could be said to be a form of illness. "If it is morally acceptable that individuals can donate their tissues to relieve the suffering of others in 'life enhancing transplants' for diseases ... we see no reason why this cannot be extended to other forms of suffering like infertility, which may or may not also be considered a disease," they said. Such a move would raise questions about consent and family permissions for posthumous donations, Parker and Hodson said, and there would also be concerns about anonymity of the donor. Britain has a shortage of donor sperm, while demand is high, and increasing, the experts said. They cited government data showing that an estimated 4,000 samples are imported to Britain each year from the United States, and 3,000 from Denmark, as well as more from other European Union countries. Sperm can be collected after death either through electrical stimulation of the prostate gland or with surgery. It can then be frozen and stored until required. Parker and Hodson cited studies showing that sperm harvested from dead men can result in healthy pregnancies and children with normal health and development, even when the sperm is retrieved 48 hours after death. Other medical experts said the analysis raised issues that need to be resolved. "Further discussion is needed to understand whether people who need to use donor sperm would even want to use the sperm of a deceased donor," said Sarah Norcross, director of the Progress Educational Trust. "It is also vital to seek the opinions of donor-conceived people about what they think the impact would be of never being able to meet the donor." Claim: Posthumous sperm donation should be allowed, say UK experts.

Ex Output:
Men in Britain should be allowed to donate sperm after they die to meet growing demand from couples seeking fertility treatment, medical experts say.

Ex Input:
Paragraph: The company earned $728 million, or 67 cents per share, in the fourth quarter. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring. "Company sales were stronger than thought, but a lot of that upside came from drugs that are already off patent or about to lose patent protection," said Edward Jones analyst Judson Clark. Excluding special items, Lilly earned 74 cents per share, matching analysts' average forecasts, according to Thomson Reuters I/B/E/S. Shares in the company dropped 1.4 percent to 53.21, after earlier reaching their lowest in two weeks at $53.05. Lilly's global sales fell 2 percent to $5.81 billion, but topped Wall Street forecasts of $5.46 billion. Sales would have been flat if not for the stronger dollar, which lowers the value of sales in overseas markets. Sales of Cymbalta, which lost U.S. patent protection last month, fell 38 percent to $883 million. But they came in about $100 million higher than Wall Street expected, analysts said. Lilly's sales, earnings, and its share price, have been badly hurt since late 2011, when its Zyprexa schizophrenia drug lost U.S. patent protection. Once Lilly's biggest product, with annual sales of $5 billion, it now has sales of only $1.5 billion. The situation worsened last month, when Cymbalta - which also had $5 billion in annual sales at its peak - began facing cheaper generics in the United States. The company's "patent cliff" will become more daunting in March, when $1 billion-a-year osteoporosis drug Evista faces U.S. generics. "We haven't wasted the crisis," Chief Executive John Lechleiter said Thursday in a conference call with industry analysts. "We're more agile, we're leaner and I believe we're better operators today." Lilly has cut more than 5,000 employees from its workforce in order to reduce annual costs by $1 billion over the last three years to deal with patent expirations on its drugs. It has also restructured itself to focus on cancer and diabetes - lucrative specialties that are two of the company's longstanding strengths. Clark said sales of Cymbalta could eventually decline 80 percent, which has been the case for many other blockbuster medicines in recent years. He questioned whether gains for other products seen in the fourth quarter will be sustainable. Sales of many products over the quarter showed double-digit sales increases, including Lilly's Humalog insulin, Cialis anti-impotence treatment, Forteo and Evista osteoporosis drugs, and Straterra for attention deficit disorder. But price increases in the United States accounted for much of those sales gains. The Indianapolis drugmaker is expecting a return to company sales growth next year, from increased sales of drugs that still have patent protection and from launches of new treatments for cancer and diabetes. It hopes to launch three new drugs this year: ramucirumab for stomach cancer, and dulaglutide and empagliflozin for type 2 diabetes - the most common form of the disease, which is closely linked to obesity. Although analysts have forecast annual sales of more than $650 million for ramucirumab, they are concerned the new diabetes drugs may have a hard time competing with similar drugs already on the market. The company has introduced no new products in recent years. In a recent interview, Lechleiter said it was time for Lilly "to go back on offense", helped by a pipeline of nearly 40 medicines in mid- and late-stage studies, compared with only seven in those stages of development a decade ago. Claim: Lilly's quarterly sales largely offset Cymbalta slide.

Ex Output:
Drugmaker Eli Lilly and Co's quarterly revenue fell far less than expected, it reported on Thursday, as plunging sales of its Cymbalta depression treatment were largely offset by higher revenues for most of its other prescription drugs.

Ex Input:
Paragraph: "In the wake of the fatal police shooting in Ferguson, Mo., Milwaukee Police Chief Edward Flynn was interviewed for nearly an hour on Wisconsin Public Radio about the incident and its implications. At one point during the Aug. 20, 2014 interview, Flynn told host Kathleen Dunn ""there are many reasons why (police) uses of force are dramatically down, and the main one is training."" Then, alluding back to Ferguson, the chief added: ""It's an extraordinarily rare event. But the fact is, (in) 2012, there were 12,197,000 arrests in the United States, OK? And there were 410 uses of deadly force. Now that is, I think, three-thousands of a percent. So, it's still an extraordinarily rare event."" In the comparison Flynn uses, there is one police killing in 0.00003 percent of all arrests -- an even tinier fraction than he suggested. But expressed another way, the 410 is an average of more than one police killing per day. So, what about the two figures themselves: Are they accurate and do they account for all of the people who are killed by police? Renewed focus Around the country, attention to the use of deadly force by police was heightened after Michael Brown, an unarmed 18-year-old, was shot to death on Aug. 9, 2014, in Ferguson, a St. Louis suburb. In Milwaukee, residents held rallies to raise questions about the Brown case and about the April 2014 death of Dontre Hamilton, a 31-year-old who was shot multiple times by a police officer during a struggle in Red Arrow Park in downtown Milwaukee. (In Milwaukee, there was one police killing of a citizen in 2012, four in 2013 and two through late August of 2014, the Police Department told us.) PolitiFact National rated Half True a claim by conservative talk show host Michael Medved that ""more whites than blacks are victims of deadly police shootings."" The claim ignored the fact that there are more than five times more whites than blacks in America. And our colleagues rated as False a statement that an unarmed black person is shot by a police officer every 28 hours. The report that had been cited by CNN pundit Marc Lamont Hill looked at all deaths, not just those of unarmed individuals. And it rolled in some deaths that did not involve police officers. Flynn's claim Flynn, who headed the police departments in Arlington, Va., and Springfield, Mass., before becoming Milwaukee's chief in 2008, is known nationally for his use of data. When we asked for evidence for Flynn's claim, a Milwaukee police spokesman cited two FBI reports. Both are from 2012, the most recent full-year statistics available. There were 12,196,959 arrests across the country in 2012, which means the figure Flynn used -- 12,197,000 -- was rounded up only slightly. The highest numbers of those arrests were for drug abuse violations, driving under the influence and larceny-theft. There were also 410 cases of justifiable homicide in 2012, according to the FBI, which defines justifiable homicide as the killing of a felon by a law enforcement officer in the line of duty. For example: A police officer responding to a bank robbery alarm who shot a suspect after the suspect fired at the officer. But that doesn't taken into account all police killings of citizens. FiveThirtyEight.com, a news website devoted to data analysis, recently reported that the 410 is a minimum figure. The numbers are self-reported by local police agencies and not audited, not all police agencies report those figures to the FBI and the number doesn't include homicides that weren't ruled justifiable. The FBI totals are likely an undercount for another reason, criminologists told us. Researchers who examine police killings of citizens within large metropolitan police departments often find that the number of such incidents recorded by the departments are higher than the number of justifiable homicides reported by the FBI. But the criminologists also noted Flynn's comparison is one legitimate way to measure the frequency of police killings. Our rating Flynn said that in 2012, there were nearly 12.2 million arrests and ""410 uses of deadly force"" by police in the United States. The Milwaukee police chief correctly quotes official FBI statistics on arrests and justifiable homicides by law enforcement officers, although it appears the 410 is an undercount of the number of people killed by police. To comment on this item, go to the Milwaukee Journal Sentinel website." Claim: "In 2012, there were nearly 12.2 million arrests and only 410 ""uses of deadly force"" by police in the United States."

Ex Output:
Flynn said that in 2012, there were nearly 12.2 million arrests and "410 uses of deadly force" by police in the United States. The Milwaukee police chief correctly quotes official FBI statistics on arrests and justifiable homicides by law enforcement officers, although it appears the 410 is an undercount of the number of people killed by police.